4D Molecular Therapeutics Inc (NAS:FDMT)
$ 25.15 0 (0%) Market Cap: 1.30 Bil Enterprise Value: 788.60 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 57/100

4D Molecular Therapeutics Inc 4D-310 Phase 1/2 and 4D-110 Phase 1/2 Clinical Data Update Call Transcript

Oct 25, 2021 / 09:00PM GMT
Operator

Hello, ladies and gentlemen. Thank you for standing by, and welcome to 4D Molecular Therapeutics 4D-310 and 4D-110 Clinical Data Conference Call. (Operator Instructions) As a reminder, today's call is being recorded. With that, I will hand over the call to Mike Zanoni, Vice President, Head of Investor Relations, who will make introductory comments.

Michael Zanoni

Thank you, Van, and welcome, everyone, to 4D Molecular Therapeutics 4D-310 and 4D-110 Clinical Data Conference Call. Today's webcasted presentation as well as this afternoon's press release describing the initial results from our Phase I/II clinical study of 4D-310 in patients with Fabry disease as well as an update on the 4D-110 choroideremia Phase I/II clinical trial are accessible in the Investors section of the 4D Molecular Therapeutics website.

With me today are Dr. David Kirn, our Co-Founder and Chief Executive Officer; Dr. Robert Fishman, our Chief Medical Officer; Dr. [Rafi] Schiffmann, our SVP and Clinical Therapeutic Area Head, Lysosomal Storage Diseases and Cardiology; and Augie Moretti,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot